We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Japanese drug ensitrelvir reduces the risk of COVID-19 infection by 67% after exposure. Phase III results in NEJM. Learn how post-exposure prophylaxis works.
